Report

Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen

See allHide authors and affiliations

Science  01 Jul 2005:
Vol. 309, Issue 5731, pp. 148-150
DOI: 10.1126/science.1109869
  • Fig. 1.

    Opsonophagocytic activity of sera specific for vaccine antigens. Live GBS bacteria of strain CJB111 were incubated for 1 hour with human PMNs in the presence of baby rabbit complement and specific antisera. The log10 of the difference between bacterial colony forming units at time = 0 and time = 1 hour are shown. Values for preimmune sera are negative because of bacterial growth during the assay. The antigens used are recorded above each bar. Shaded bars represent specific immune sera; open bars, the corresponding preimmune sera from the same animals. Error bars indicate standard deviation.

  • Table 1.

    Protection conferred by four antigens against six GBS strains assessed by active maternal immunization/neonatal pup challenge model. Female mice received three doses (days 1, 21, 35) of either 20 μg antigen or phosphate-buffered saline (PBS) combined with Freund's adjuvant. Mice were then mated, and the resulting offspring challenged with a dose of GBS calculated to kill 80 to 90% of the pups. Survival of pups was monitored for 2 days after challenge. Fluorescence given in -fold difference between cells stained with immune sera versus pre-immune sera. Protection values calculated as [(% dead in control – % dead in vaccine)/% dead in control] × 100. ND, not determined.

    GBS strain Type Fluorescence immune/preimmune Protein alive/treated PBS alive/treated Protection (%) Statistical significance (P value)
    Antigen GBS 80
    515 Ia 0* 1/30 4/38 >0.05
    7357 B Ib 2.2 11/28 13/32 >0.05
    DK21 II 0* 4/30 4/19 >0.05
    COH1 III 7.5 26/29 3/29 88.5 <0.0001
    2603 V/R V 1.5 13/40 8/30 7.5 >0.05
    CJB111 V 9.0 23/35 11/49 56.0 0.0001
    Antigen GBS 67
    515 Ia 10.1 19/30 5/29 55.8 0.0005
    7357 B Ib 7.8 10/20 5/34 41.2 0.01
    DK21 II 8.1 27/40 9/40 58.3 0.0001
    COH1 III 0* 7/30 5/30 7.6 >0.05
    2603 V/R V 2.6 5/29 7/40 2.9 >0.05
    CJB111 V 11.8 29/37 1/39 77.9 <0.0001
    Antigen GBS 104
    515 Ia 0* ND ND
    7357 B Ib 6/39 13/32 >0.05
    DK21 II 0* 5/38 7/40 >0.05
    COH1 III 5.6 22/40 7/33 43.0 0.0041
    2603 V/R V 9/30 8/30 4.1 >0.05
    CJB111 V 5.8 32/48 7/26 54.3 0.0014
    Antigen GBS 322
    515 Ia 5.6 23/25 9/21 86.0 0.0004
    7357 B Ib 2.5 22/46 13/32 11.6 >0.05
    DK21 II 8.4 28/40 6/24 60.0 0.0007
    COH1 III 3.2 2/30 3/29 >0.05
    2603 V/R V 7.2 36/42 12/32 77.3 <0.0001
    CJB111 V 1.4 ND ND ND ND
    • * Gene missing in this strain.

  • Table 2.

    Protection against 12 GBS strains by a four-antigen combination. Experiments were performed as in Table 1 except that mice were vaccinated with a mixture of 15 μg of each protein (a total of 60 μg). Protection P values were less than 0.0001.

    GBS strain Serotype Vaccine (alive/treated) PBS (alive/treated) Protection
    515 Ia 39/40 6/40 97.0%
    DK1 Ia 50/50 8/38 82.5%
    7357B Ib 49/60 5/46 79.4%
    DK21 II 25/34 17/48 59.3%
    5401 II 35/40 3/37 86.4%
    3050 II 48/48 1/30 100%
    COH1 III 36/36 7/40 100%
    M781 III 30/40 4/39 72.0%
    2603V/R V 27/33 10/35 75.0%
    CJB111 V 25/28 4/46 88.2%
    JM9130013 VIII 37/39 5/40 94.2%
    SMU071 VIII 44/50 18/50 81.2%
    Total   445/498 88/498 87.0%

Additional Files


  • Abstract
    Full Text
    Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen
    Domenico Maione, Immaculada Margarit, Cira D. Rinaudo, Vega Masignani, Marirosa Mora, Maria Scarselli, Hervé Tettelin, Cecilia Brettoni, Emilia T. Iacobini, Roberto Rosini, Nunzio D�Agostino, Lisa Miorin, Scilla Buccato, Massimo Mariani, Giuliano Galli, Renzo Nogarotto, Vincenzo Nardi Dei, Filipo Vegni, Claire Fraser, Giuseppe Mancuso, Giuseppe Teti, Lawrence C. Madoff, Lawrence C. Paoletti, Rino Rappuoli, Dennis L. Kasper, John L. Telford, Guido Grandi

    Supporting Online Material

    This file is in Adobe Acrobat PDF format. If you have not installed and configured the Adobe Acrobat Reader on your system, please see Help with Printing for instructions.

    This supplement contains:

    Materials and Methods
    Tables S1 and S2
    References and Notes

    Download supplement

Navigate This Article